Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CCR3 | P51677 | 3/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28628657 | 1.00 | RAB9A (0.44) | RAB9AGAACCR3ABCB1PTPRB | |
| SCHEMBL28634360 | 0.83 | GAA (0.40) | RAB9AGAACCR3ABCB1PTPRB | |
| SCHEMBL28634359 | 0.83 | GAA (0.40) | RAB9AGAACCR3ABCB1PTPRB | |
| SCHEMBL28629445 | 0.82 | ABCB1 (0.43) | RAB9AGAAABCB1PTPRBMAPT | |
| SCHEMBL28629446 | 0.82 | ABCB1 (0.43) | RAB9AGAAABCB1PTPRBMAPT | |
| SCHEMBL22154608 | 0.81 | ABCB1 (0.42) | RAB9AGAACCR3ABCB1PTPRB | |
| SCHEMBL28631041 | 0.81 | ABCB1 (0.42) | RAB9AGAACCR3ABCB1PTPRB | |
| SCHEMBL28646537 | 0.80 | GAA (0.37) | RAB9AGAACCR3MAPT | |
| SCHEMBL28924140 | 0.76 | FAP (0.37) | RAB9AGAACCR3ABCB1 | |
| SCHEMBL22154257 | 0.73 | GAA (0.43) | RAB9AGAACCR3ABCB1PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-113454097-A | Tubulysins and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | SDCBP, TEK, TEKT1 | RAB9A 1892/4885GAA 1543/4885CCR3 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.